AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03373331 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Exercises
Description: Participants in the control group will receive computerized control exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
Study NCT00441792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Midazolam at induction dose based on weight
Study NCT02733874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Clobetasol Propionate Ointment
Study NCT02733874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol Betamethasone Ointment
Study NCT03715426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MKit
Description: MKit is a web-based application that uses a life-skills approach to address healthy relationships and sexual violence. It includes 14 tiles which incorporate information, goal setting, and resources.
Study NCT03437239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delfi PTS II Portable Tourniquet System
Description: This is a portable tourniquet system that allows for occlusion of venous outflow without inhibiting arterial blood flow. This portable tourniquet system allows for rapid cuff inflation and deflation with a battery. The Delfi PTS is a purpose-built system that allows for precise control of pressure throughout training, despite the natural changes in muscle shape and length. The device has advanced pressure leak detection that monitors the tourniquet cuff, tubing, and connectors for air leaks and safely alerts staff to hazards or follow-up actions required. The device has visual and audio alarms for over and under pressure and elapsed time as well as a large, easily visible display of tourniquet pressure and elapsed time. The Delfi PTS II calibrates and self-tests on startup. It has a safety interlock that limits the normal maximum pressure and integrated tourniquet cuff testing as recommended in current AORN Standards and Recommended Practices
Study NCT02069665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin Injection
Description: ivd. 10 to 20 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.
Study NCT02069665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiaoer Qingfei Heji (mixture)
Description: children aged 6 months to 1 year old: 10 ml, orally taken three times daily; children aged 1 to 3 year old: 15 ml, orally taken three times daily; children aged 3 to 5 year old: 20 ml, orally taken three times daily;
Study NCT03664375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: All patients in the experimental group received a BoNT-A injection. The injected total dose for individual patient in the experimental group was 100 units which is equivalent to approximately 300-500 Units of Dysport (the other type of BoNT-A available). The Botox was injected by the neurophysician intramuscularly using insulin U100 syringe and determination of muscles for injection was assessed clinically.
Study NCT03664375 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Task Specific Training
Description: Task specific training is the repetition of a specific task until expertise is reached. More challenging tasks are added as a means of progression
Study NCT03664375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task Specific Training
Description: Task specific training is the repetition of a specific task until expertise is reached. More challenging tasks are added as a means of progression
Study NCT01187992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg/day
Study NCT01302873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGG492A
Study NCT01302873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BGG492A
Study NCT02100904 — intervention group
Intervention type: PROCEDURE
Intervention: Radiofrequency ablation of fibroids
Study NCT02100904 — intervention group
Intervention type: PROCEDURE
Intervention: Myomectomy of fibroids
Study NCT00454493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omacor (omega-3-acid ethyl esters)
Study NCT00454493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omacor (omega-3-acid ethyl esters)
Study NCT00047346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study NCT00047346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00047346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00878839 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Toric
Description: AcrySof Toric IOL
Study NCT02069665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zhi Ke San
Description: children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;
Study NCT02069665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hua Tan San
Description: children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;
Study NCT02069665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guaifenesin Syrup
Description: children aged 6 months to 1 year old: 3ml, orally taken three times daily; children aged 1 to 3 year old: 5ml, orally taken three times daily; children aged 3 to 5 year old: 8ml, orally taken three times daily;
Study NCT03096587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XP Endo Finisher
Description: a flexible single use NiTi file with small diameter and no taper, changes from straight M-phase to A-phase in body temperature
Study NCT03096587 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonic activated irrigation
Description: by Satelec,Acteon, France
Study NCT04642742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Chewable plant sterol
Description: Chewable plant sterol (gummy)
Study NCT03543410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-4199 200 mg
Description: SEP-4199 200 mg/day (supplied in two 100mg tablets)
Study NCT03543410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-4199 400 mg
Description: SEP-4199 400 mg/day (supplied in two 200mg tablets
Study NCT03543410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (supplied in two tablets/day)
Study NCT02902120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-transplant Grazoprevir and Elbasvir
Description: Treatment will be started in the post-transplant patients on day 0 with the combination pill zepatier, containing grazoprevir 100mg/elbasvir 50mg by mouth once daily. The medications will be continued for a total of 12 weeks (16 weeks if resistance mutations, RAVs, are detected)
Study NCT02952976 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abthera
Description: ABThera group technique the dressing will be done according to the description and the manufacturer's instructions (Acelity, San Antonio, TX).
Study NCT02952976 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Barker
Description: In Barker Group a fenestrated plastic will be used and that will be in contact with viscera followed by four pads with a suction drain and an adhesive finishing layer.
Study NCT04697329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preincisional infiltration with levobupivacaine
Description: Local, preincisional infiltration of port sites with levobupivacaine 5 mg/ml 20 ml
Study NCT00666926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF00562271
Description: 125 mg twice daily \[BID\] with food, tablet
Study NCT00666926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF00562271
Description: 125 mg BID with food, tablet
Study NCT00983190 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Left Ventricular Assist Device (HeartMate II)
Description: The HM II is a high speed, electric, axial flow, rotary blood pump. The pump drains blood from the left ventricular apex via rigid inlet cannulae and ejects into the aortic root via an outflow cannula joined to the aorta with an end to side anastamosis. Power and control of the pump are delivered through a percutaneous cable from pump to the belt-worn System Controller. The System Controller will receive power from the Power Base Unit (PBU), or two battery modules that may be worn in shoulder holsters or on the belt
Study NCT04148261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Acetate (CORT)
Description: Participants will receive a single dose of hydrocortisone at a dosage of 0.65 mg/kg
Study NCT04148261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone Acetate (CORT)
Description: Participants will receive a single dose of hydrocortisone at a dosage of 0.65 mg/kg
Study NCT04148261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine Sulfate (EPI)
Description: Participants will receive a continuous infusion of epinephrine at a dosage of 80 ng/kg/min
Study NCT04148261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine Sulfate (EPI)
Description: Participants will receive a continuous infusion of epinephrine at a dosage of 80 ng/kg/min
Study NCT04148261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PLB)
Description: Participants will receive a placebo
Study NCT04148261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (PLB)
Description: Participants will receive a placebo
Study NCT01096147 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal cord stimulation with eight polar electrode
Description: In SCS a lead is positioned in the epidural space on the dorsal aspect of the spinal cord as to produce electrically induced paraesthesia in the painful area.
Study NCT02736032 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: The transfer of cryopreserved-thawed embryos inside the uterus aiming to achieve pregnancy
Study NCT02736032 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serum Estradiol and Progesterone levels
Description: Serum estradiol and serum progesterone levels in blood on the day of start of progesterone supplementation
Study NCT02736032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist
Description: GnRH agonist given on day 21 of the cycle preceding the embryo transfer
Study NCT02736032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: External Estradiol
Description: Estradiol started on day1 of the cycle for endometrial prepartaion
Study NCT02736032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: progesterone as luteal phase support start after endometrium is well prepared
Study NCT01263041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: enteral or via NG tube dose of 312mg/kg/day divided every 12 hours from starting feeding + usual care and medications up to 30 says post natal age
Study NCT01263041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: l-arginine
Description: enteral or via NG tube dose of 260mg/kg/day divided every 12 hours from starting feeding + usual care and medications up to 30 says post natal age
Study NCT06011720 — intervention group
Intervention type: OTHER
Intervention: Improved transition of care.
Description: Evaluation of how early physiatry consultation after acute stroke affects length of stay and resulting outcomes.
Study NCT04458844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Intervention programmes were designed based on previous research (Duncan, et al., 2017; Faigenbaum, et al., 2011; Miller, et al., 2006) to ensure all exercises were developmentally appropriate for the age of the participants (an example session plan can be seen in the supplementary material). Each session consisted of five activities and lasted 50 - 60 minutes. Three out of the five activities were identical for the FMS and FMS+ groups, while two differed focusing on skill development for the FMS group and strength development for the FMS+ group. The FMS and FMS+ group received their sessions twice a week for 4 weeks. The sessions were delivered at least 48 hours apart to allow recovery and to reduce the risk of fatigue effecting performance (Faigenbaum, et al., 1996). All sessions were led by a researcher and a qualified sports coach.
Study NCT02069665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Suspension
Description: taken under prescription
Study NCT02069665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salbutamol
Description: taken under prescription
Study NCT01101802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Arm 1 patients were given 1 gm bd mycophenolate mofetil for 8 weeks, The mycophenolate was dispensed as 500mg tablets.
Study NCT01101802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: Arm 2 patients were given 2 sugar pills bd for 8 weeks
Study NCT03664232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279
Description: Participants will receive 25 mg JNJ-42165279 orally twice daily for 12 weeks.
Study NCT03162900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib Therapeutic Exposure
Description: Subjects Receive a single 150 mg dose of Glasdegib followed by ECG and PK assessments.
Study NCT03162900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib Supra-therapeutic Exposure
Description: Subjects receive a single 300 mg dose of glasdegib followed by ECG and PK assessments.
Study NCT03664232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a matching placebo orally twice daily for 12 weeks.
Study NCT03415828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ethanol gel
Description: Intradiscal injection of ethanol gel
Study NCT03415828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate
Description: Intradiscal infiltration of steroids
Study NCT01902173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a biopsy
Study NCT01902173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT01902173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan
Study NCT01902173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib Mesylate
Description: Given PO
Study NCT01902173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT01902173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib Dimethyl Sulfoxide
Description: Given PO
Study NCT03162900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Positive Control (Moxifloxacin)
Description: Subjects will receive a single 400 mg dose of moxifloxacin followed by ECG and PK assessments.
Study NCT03162900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Control
Description: Subjects will receive placebo dose followed by ECG and PK assessments.
Study NCT01093703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication Adjustment
Description: 1. Awake SBP≤135/85mmHg and patient is on once daily medications: Switch BP medications to pm period.~2. Awake SBP SBP≤135/85mmHg and patient is on bid medications (e.g. metoprolol bid): Increase pm dose of the medication. If medication is already is at maximal dose or there is contraindication for increasing the dose (e.g. bradycardia), add another BP medicine in the evening time.~3. Awake SBP≤135/85mmHg and patient is not on anti-hypertensive medications: Add BP medication at the pm period.~4. Awake SBP>135/85mmHg: increase dose of antihypertensive medications or add more medications. All medications to be given in the evening time.
Study NCT02885116 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal high flow (NHF) supplementation
Description: use of NHF for 20 min/ 35 l/min, at the end of this period right heart catheterization
Study NCT02885116 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: oxygen supplementation
Description: hypoxemic patients will use their normal oxygen supplementation durch right heart catheterization
Study NCT04477278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: The mindfulness meditation recording consisted of instruction in focused attention on breath and body sensations and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and pain.
Study NCT04477278 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: History of Osteopathy
Description: The history of osteopathy recording introduced patients to the founder of osteopathy, Andrew Taylor Still, and his philosophy of healing.
Study NCT04489069 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI
Description: Magnetic Resonance Imaging (sturctural MRI, fMRI resting state and task related, DTI)
Study NCT04489069 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Clinical and Neuropsychological evaluations
Description: Clinical interviews and neuropsychological tests (paper/pencil and computer based)
Study NCT04489069 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Drawing DNA sample
Description: Saliva sample
Study NCT03728205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Twice weekly yoga sessions for 12 weeks
Study NCT04172558 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: a single ICI of BTX-A 100 units one day after the penile Doppler/trimix test.
Study NCT04172558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimix
Description: on demand ICI of Trimix
Study NCT00681239 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified Atkins diet and KetoCal
Description: 10 gram per day Modified Atkins diet and 10 oz per day of KetoCal shake.
Study NCT02239822 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation of the trigeminal nerve (active stimulation)
Description: Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks. the duration of the open label trial will be more 24 weeks.
Study NCT02239822 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo stimulation of the trigeminal nerve (placebo)
Description: Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks.
Study NCT04110041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Thrice-weekly aerobic exercise sessions lasting \~45 minutes, for 12 consecutive weeks.
Study NCT01154933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide 5 mcg
Description: exenatide 5 mcg
Study NCT01154933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide 10 mcg
Description: exenatide 10 mcg
Study NCT01154933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline sq
Study NCT02978482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: durvalumab (MEDI4736) 20mg/kg via IV infusion every 4 weeks until confirmed disease progression or unacceptable toxicity
Study NCT02978482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tremelimumab + durvalumab
Description: 20 mg/kg durvalumab (MEDI4736) via IV infusion q4w and 1 mg/kg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 20 mg/kg durvalumab (MEDI4736) q4w starting on Week 16 for up to confirmed disease progression
Study NCT01037673 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: A progressive program where load and complexity increases during a 3 month period. Initially PT-tutored every week and then every other week.